Log in to search using one of your social media accounts:

 

Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome

Conditions:   Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Refractory High Risk Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Therapy-Related Myelodysplastic Syndrome Interventions:   Drug: Ibrutinib;   Drug: Lenalidomide Sponsors:   University of California, Davis;   Pharmacyclics LLC.;   Celgene;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

(In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes, Published online: 22 February 2018; doi:10.1038/s41375-018-0064-6(In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes
Source: Leukemia - Category: Hematology Authors: Source Type: research
Conclusions Multiparametric analyses of new automated parameters are useful for discriminating MDS from non-clonal cytopenia.
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
• Improving IPSS-R before transplant did not translate into better survival outcome.• Blast count pre-transplant was highly predictive of post-transplant outcome.• Survival outcome was affected by cytogenetic at diagnosis and the status of cGVHD.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Publication date: Available online 19 February 2018 Source:The Journal of Molecular Diagnostics Author(s): Andreas Bräuninger, Wolfgang Blau, Kristin Kunze, Ann-Kathrin Desch, Alexander Brobeil, Mehmet Kemal Tur, Benjamin Etschmann, Ulrich Günther, Dieter Körholz, Georg Schliesser, Andreas Käbisch, Michael Kiehl, Mathias Rummel, Stefan Gattenlöhner Myelodysplastic syndromes are hematological neoplasias in which immunohistological examination of bone-marrow trephines is important for a definite diagnosis. Unequivocal distinction from reactive bone-marrow changes is, however, sometimes difficult. As...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Source: American Journal of Hematology - Category: Hematology Authors: Tags: Commentary Source Type: research
Condition:   Myelodysplastic Syndromes Intervention:   Drug: 50 gm CIVI/24 hours x 5 days every 4 week Sponsors:   New York University School of Medicine;   Perlmutter Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Myelodysplastic Syndromes Intervention:   Drug: 50 gm CIVI/24 hours x 5 days every 4 week Sponsors:   New York University School of Medicine;   Perlmutter Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Transplant-Related Hematologic Malignancy;   Leukemia, Acute;   Myelodysplastic Syndromes;   Graft Vs Host Disease;   Fungal Infection Interventions:   Drug: Conditioning treatment " Thiotepa-Treosulfan-Fludarabine " ;   Procedure: PBSC graft;   Drug: GvHD prophylaxis;   Drug: Primary antifungal prophylaxis Sponsor:   Ciceri Fabio Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Myelodysplastic Syndromes Intervention:   Drug: 50 gm CIVI/24 hours x 5 days every 4 week Sponsors:   New York University School of Medicine;   Perlmutter Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Myelodysplastic Syndrome | Revlimid